Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 5/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 8/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.36 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL381380 | 0.94 | TP53 (0.39) | PRCPHSD11B1DPP4DPP7DPP8 | |
| Trifluoroacetic Acid SCHEMBL381484 | 0.93 | P2RY14 (0.37) | HSD11B1DPP4DPP7DPP8KCNH2 | |
| SCHEMBL3564428 | 0.92 | HTR2A (0.43) | HTR2AHTR2CHSD11B1ROCK2CHRM2 | |
| SCHEMBL3564422 | 0.92 | HTR2A (0.43) | HTR2AHTR2CHSD11B1ROCK2CHRM2 | |
| Trifluoroacetic Acid SCHEMBL381863 | 0.91 | AKR1C2 (0.41) | HTR2CHSD11B1CHRM2CHRM1CHRM3 | |
| Trifluoroacetic Acid SCHEMBL381517 | 0.91 | PAX8 (0.35) | HSD11B1DPP4DPP7DPP8DPP9 | |
| Trifluoroacetic Acid SCHEMBL380290 | 0.89 | HTR2A (0.46) | PRCPHTR2AHTR2CHSD11B1GPR17 | |
| Trifluoroacetic Acid SCHEMBL380699 | 0.89 | FFAR4 (0.35) | HTR2ADPP4DPP7DPP8DPP9 | |
| Trifluoroacetic Acid SCHEMBL380865 | 0.87 | S1PR5 (0.38) | HSD11B1CHRM3 | |
| Trifluoroacetic Acid SCHEMBL380667 | 0.86 | RAD52 (0.39) | KCNH2CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049513-B1 | PIPERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2012-01-25 | — | — | EP | disclosed |
| US-7829582-B2 | Piperidinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2010-11-09 | — | — | US | disclosed |
| EP-2049513-A1 | PIERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Eli Lilly & Company (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20090088430-A1 | PIERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-04-02 | — | — | US | disclosed |
| WO-2007127901-A1 | PIERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088430-A1 | PIERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD17B1, HSD3B1 | PRCP 2729/4885HTR2A 1473/4885HTR2C 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.